ATE286034T1 - N-((substitutierte fünfgliedrige di- oder triaza- doppeltungesättigter ring)carbonyl)guanidinderivate zur behandlung von ischemie - Google Patents
N-((substitutierte fünfgliedrige di- oder triaza- doppeltungesättigter ring)carbonyl)guanidinderivate zur behandlung von ischemieInfo
- Publication number
- ATE286034T1 ATE286034T1 AT99901083T AT99901083T ATE286034T1 AT E286034 T1 ATE286034 T1 AT E286034T1 AT 99901083 T AT99901083 T AT 99901083T AT 99901083 T AT99901083 T AT 99901083T AT E286034 T1 ATE286034 T1 AT E286034T1
- Authority
- AT
- Austria
- Prior art keywords
- guanidene
- triaza
- ischemia
- membered
- carbonyl
- Prior art date
Links
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical class [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 title 1
- 208000028867 ischemia Diseases 0.000 title 1
- 229920006395 saturated elastomer Polymers 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7636298P | 1998-02-27 | 1998-02-27 | |
| PCT/IB1999/000206 WO1999043663A1 (en) | 1998-02-27 | 1999-02-05 | N-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE286034T1 true ATE286034T1 (de) | 2005-01-15 |
Family
ID=22131525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99901083T ATE286034T1 (de) | 1998-02-27 | 1999-02-05 | N-((substitutierte fünfgliedrige di- oder triaza- doppeltungesättigter ring)carbonyl)guanidinderivate zur behandlung von ischemie |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US6492401B1 (de) |
| EP (2) | EP1454902A1 (de) |
| JP (2) | JP2002504546A (de) |
| KR (4) | KR20030078886A (de) |
| CN (1) | CN1289326A (de) |
| AP (1) | AP9901478A0 (de) |
| AR (1) | AR015526A1 (de) |
| AT (1) | ATE286034T1 (de) |
| AU (1) | AU739403B2 (de) |
| BG (1) | BG104803A (de) |
| BR (1) | BR9908332A (de) |
| CA (1) | CA2321642A1 (de) |
| CO (1) | CO4980897A1 (de) |
| DE (1) | DE69922930T2 (de) |
| DK (1) | DK1056729T3 (de) |
| DZ (1) | DZ2729A1 (de) |
| EA (1) | EA003603B1 (de) |
| ES (1) | ES2237080T3 (de) |
| GT (1) | GT199900022A (de) |
| HR (2) | HRP20010666A2 (de) |
| HU (1) | HUP0204418A3 (de) |
| ID (1) | ID25505A (de) |
| IL (1) | IL136588A0 (de) |
| IS (1) | IS5548A (de) |
| NO (1) | NO20004192L (de) |
| NZ (1) | NZ504769A (de) |
| OA (1) | OA11450A (de) |
| PA (1) | PA8468401A1 (de) |
| PE (1) | PE20000334A1 (de) |
| PL (1) | PL342444A1 (de) |
| PT (1) | PT1056729E (de) |
| SI (1) | SI1056729T1 (de) |
| SK (1) | SK12342000A3 (de) |
| TN (1) | TNSN99028A1 (de) |
| TR (1) | TR200002480T2 (de) |
| TW (1) | TWI226329B (de) |
| WO (1) | WO1999043663A1 (de) |
| YU (1) | YU46200A (de) |
| ZA (1) | ZA991578B (de) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002504546A (ja) * | 1998-02-27 | 2002-02-12 | ファイザー・プロダクツ・インク | 虚血の治療のためのｎ−［（置換５員ジもしくはトリアザ二不飽和環）カルボニル］グアニジン誘導体 |
| FR2795726A1 (fr) * | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
| UA72002C2 (en) * | 1999-10-29 | 2005-01-17 | Pfizer Prod Inc | Inhibitors crystals of sodium-hydrogen exchange of 1 type, a method for the preparation thereof (variants), a pharmaceuticalcomposition based thereon and a method for the reduction of tissue damage |
| US6441176B1 (en) | 1999-10-29 | 2002-08-27 | Pfizer Inc. | Method for preparing sodium-hydrogen exchanger type 1 inhibitor |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| US6570013B2 (en) | 2000-02-16 | 2003-05-27 | Pfizer Inc | Salts of zopolrestat |
| US6555569B2 (en) * | 2000-03-07 | 2003-04-29 | Pfizer Inc. | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| MXPA02010222A (es) | 2000-04-18 | 2003-05-23 | Agouron Pharma | Pirazoles para inhibir proteina cinasa. |
| AP2002002651A0 (en) * | 2000-04-28 | 2002-12-31 | Pfizer Prod Inc | Sodium-hydrogen exchanger type 1 inhibitor (nhe-1) |
| US6852733B2 (en) * | 2000-04-28 | 2005-02-08 | Pfizer Inc. | Sodium-hydrogen exchanger type 1 inhibitor |
| IL144507A0 (en) * | 2000-07-31 | 2002-05-23 | Pfizer Prod Inc | Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
| EP1337508A1 (de) * | 2000-11-28 | 2003-08-27 | Pfizer Products Inc. | Verfahren zur herstellung eines natrium-wasserstoff-austauschers typ 1 inhibitor |
| IL147696A0 (en) * | 2001-01-25 | 2002-08-14 | Pfizer Prod Inc | Combination therapy |
| US6423705B1 (en) | 2001-01-25 | 2002-07-23 | Pfizer Inc. | Combination therapy |
| CA2436539A1 (en) * | 2001-01-31 | 2002-08-08 | Pfizer Products Inc. | Ethanolates of sodium-hydrogen exchanger type-1 inhibitor |
| WO2002098429A1 (en) * | 2001-06-07 | 2002-12-12 | Pfizer Products Inc. | Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat |
| US7358267B2 (en) * | 2001-06-29 | 2008-04-15 | Amgen Inc. | Bis-aryl thiazole derivatives |
| PL369074A1 (en) * | 2001-11-02 | 2005-04-18 | Aventis Pharmaceuticals Inc. | Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor |
| BR0215002A (pt) | 2001-12-19 | 2004-11-09 | Pfizer Prod Inc | Métodos de preparação de inibidores de permutadores de sódio-hidrogênio de tipo 1 |
| EP1472242A1 (de) * | 2002-01-30 | 2004-11-03 | Pfizer Products Inc. | Pharmazeutische zusammensetzungen, zoniporide mesylat enthaltend und prozesse zur verbesserung der löslichkeit von zoniporide |
| CA2483927A1 (en) * | 2002-05-02 | 2003-11-13 | Pfizer Products Inc. | Treatment of diabetes and diabetic complications with nhe-1 inhibitors |
| US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| FR2840302B1 (fr) * | 2002-06-03 | 2004-07-16 | Aventis Pharma Sa | Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
| FR2842524B1 (fr) * | 2002-07-16 | 2005-04-22 | Aventis Pharma Sa | Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-pyrrole, leur procede de preparation a titre de medicaments |
| FR2842525B1 (fr) * | 2002-07-16 | 2005-05-13 | Aventis Pharma Sa | Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant |
| FR2842526B1 (fr) | 2002-07-16 | 2007-07-13 | Aventis Pharma Sa | Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments |
| US7365070B2 (en) * | 2002-12-04 | 2008-04-29 | Ore Pharmaceuticals Inc. | Modulators of melanocortin receptor |
| ZA200505734B (en) * | 2003-02-07 | 2006-12-27 | Daiichi Seiyaku Co | Pyrazole Derivative |
| SG134333A1 (en) | 2003-11-12 | 2007-08-29 | Phenomix Corp | Heterocyclic boronic acid compounds |
| US7576121B2 (en) | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| US7317109B2 (en) | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| TW200526641A (en) * | 2003-12-26 | 2005-08-16 | Daiichi Seiyaku Co | Amidopyrazole derivatives |
| WO2005079803A1 (en) * | 2004-02-13 | 2005-09-01 | Pfizer Products, Inc. | Compounds for treatment of cardiovascular diseases |
| EP1778220A1 (de) | 2004-07-12 | 2007-05-02 | Phenomix Corporation | Eingezwängte cyano-verbindungen |
| US7223786B2 (en) | 2004-11-15 | 2007-05-29 | Bristol-Myers Squibb Company | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
| US7226942B2 (en) | 2004-11-15 | 2007-06-05 | Bristol-Myers Squibb Company | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| WO2006053274A2 (en) | 2004-11-15 | 2006-05-18 | Bristol-Myers Squibb Company | 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| WO2006055463A2 (en) | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| JP2008526816A (ja) * | 2005-01-10 | 2008-07-24 | デビオファーム ソシエテ アノニム | 心筋虚血状態の間の投与のための薬剤の製造のための環状ウンデカペプチドの使用 |
| US20060235028A1 (en) | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
| US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| EP2046753A2 (de) | 2006-07-06 | 2009-04-15 | Brystol-Myers Squibb Company | Pyridon/hydroxypyridin-11-beta-hydroxysteroid-dehydrogenase-hemmer vom typ i |
| US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| EP2142551B1 (de) | 2007-04-17 | 2015-10-14 | Bristol-Myers Squibb Company | KONDENSIERTE HETEROCYCLISCHE Verbindungen als Hemmer der BETA-HYDROXYSTEROID-DEHYDROGENASE -TYP I |
| ES2408384T3 (es) | 2007-07-27 | 2013-06-20 | Bristol-Myers Squibb Company | Nuevos activadores de glucoquinasa y procedimientos de uso de los mismos |
| PT2294066E (pt) * | 2008-04-28 | 2014-11-21 | Janssen Pharmaceutica Nv | Benzoimidazoles como inibidores da prolil-hidroxilase |
| US10517839B2 (en) | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
| MX2011005221A (es) * | 2008-11-21 | 2011-08-03 | Raqualia Pharma Inc | Nuevo derivado de la pirazol-3-carboxamida que tiene actividad de antagonista del receptor de 5-ht2b. |
| WO2010094090A2 (en) * | 2009-02-18 | 2010-08-26 | Katholleke Universiteit Leuven | Synucleinopathies |
| CN102971313A (zh) | 2010-04-14 | 2013-03-13 | 百时美施贵宝公司 | 新颖的葡糖激酶激活剂及其使用方法 |
| CN102408385B (zh) * | 2011-06-20 | 2014-06-18 | 雅本化学股份有限公司 | 一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法 |
| CN102408386B (zh) * | 2011-07-27 | 2014-05-07 | 雅本化学股份有限公司 | 2,4-二取代-2h-1,2,3-三氮唑衍生物的制备方法 |
| BR112014006940A2 (pt) | 2011-09-23 | 2017-04-04 | Bayer Ip Gmbh | uso de derivados de ácido 1-fenilpirazol-3-carboxílico 4-substituído como agentes contra estresse abiótico em plantas |
| WO2013063221A1 (en) | 2011-10-25 | 2013-05-02 | Janssen Pharmaceutica Nv | Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid |
| WO2013130411A1 (en) | 2012-02-27 | 2013-09-06 | Essentialis, Inc. | Salts of potassium atp channel openers and uses thereof |
| AU2016301745B2 (en) | 2015-08-06 | 2020-07-16 | Ube Industries, Ltd. | Substituted guanidine derivative |
| WO2017057695A1 (ja) * | 2015-09-30 | 2017-04-06 | 東レ株式会社 | ジフェニルピラゾール誘導体及びその医薬用途 |
| WO2017104741A1 (ja) | 2015-12-16 | 2017-06-22 | 日本曹達株式会社 | アリールアゾール化合物および有害生物防除剤 |
| US10344002B2 (en) | 2016-09-26 | 2019-07-09 | Nusirt Sciences, Inc. | Compositions and methods for treating metabolic disorders |
| CN108017584B (zh) * | 2017-06-20 | 2021-03-23 | 南开大学 | A3腺苷受体的小分子拮抗剂 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2104931B1 (de) * | 1970-09-08 | 1975-01-10 | Ferlux | |
| CA2121391A1 (en) | 1993-04-28 | 1994-10-29 | Atsuyuki Kojima | Indoloylguanidine derivatives |
| IL109570A0 (en) * | 1993-05-17 | 1994-08-26 | Fujisawa Pharmaceutical Co | Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
| EP0639573A1 (de) * | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament |
| US5852046A (en) | 1993-08-03 | 1998-12-22 | Hoechst Aktiengesellschaft | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them |
| DE4412334A1 (de) | 1994-04-11 | 1995-10-19 | Hoechst Ag | Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| CA2160600A1 (en) * | 1994-10-18 | 1996-04-19 | Masahumi Kitano | Indoloylguanidine derivatives |
| NZ314105A (en) | 1996-02-02 | 1997-12-19 | Sumitomo Pharma | Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring |
| JPH09291076A (ja) | 1996-04-24 | 1997-11-11 | Sumitomo Pharmaceut Co Ltd | 置換グアニジン誘導体およびその製法 |
| ZA9711102B (en) * | 1996-12-16 | 1998-08-13 | Yamanouchi Pharma Co Ltd | N-[(substituted 5-membered heteroaryl)carbonyl] guanidine derivative |
| JP2002504546A (ja) * | 1998-02-27 | 2002-02-12 | ファイザー・プロダクツ・インク | 虚血の治療のためのｎ−［（置換５員ジもしくはトリアザ二不飽和環）カルボニル］グアニジン誘導体 |
-
1999
- 1999-02-05 JP JP2000533420A patent/JP2002504546A/ja active Pending
- 1999-02-05 AT AT99901083T patent/ATE286034T1/de not_active IP Right Cessation
- 1999-02-05 US US09/367,731 patent/US6492401B1/en not_active Expired - Fee Related
- 1999-02-05 HR HR20010666A patent/HRP20010666A2/hr not_active Application Discontinuation
- 1999-02-05 KR KR10-2003-7009644A patent/KR20030078886A/ko not_active Ceased
- 1999-02-05 YU YU46200A patent/YU46200A/sh unknown
- 1999-02-05 IL IL13658899A patent/IL136588A0/xx unknown
- 1999-02-05 KR KR10-2003-7012300A patent/KR20030083004A/ko not_active Ceased
- 1999-02-05 BR BR9908332-9A patent/BR9908332A/pt not_active IP Right Cessation
- 1999-02-05 EA EA200000789A patent/EA003603B1/ru not_active IP Right Cessation
- 1999-02-05 HR HR20000550A patent/HRP20000550A2/hr not_active Application Discontinuation
- 1999-02-05 ID IDW20001633A patent/ID25505A/id unknown
- 1999-02-05 PT PT99901083T patent/PT1056729E/pt unknown
- 1999-02-05 AU AU20706/99A patent/AU739403B2/en not_active Ceased
- 1999-02-05 SK SK1234-2000A patent/SK12342000A3/sk unknown
- 1999-02-05 DK DK99901083T patent/DK1056729T3/da active
- 1999-02-05 ES ES99901083T patent/ES2237080T3/es not_active Expired - Lifetime
- 1999-02-05 CA CA002321642A patent/CA2321642A1/en not_active Abandoned
- 1999-02-05 KR KR10-2000-7009529A patent/KR100449600B1/ko not_active Expired - Fee Related
- 1999-02-05 KR KR10-2002-7017553A patent/KR100407903B1/ko not_active Expired - Fee Related
- 1999-02-05 NZ NZ504769A patent/NZ504769A/en unknown
- 1999-02-05 DE DE69922930T patent/DE69922930T2/de not_active Expired - Fee Related
- 1999-02-05 WO PCT/IB1999/000206 patent/WO1999043663A1/en not_active Ceased
- 1999-02-05 PL PL99342444A patent/PL342444A1/xx not_active Application Discontinuation
- 1999-02-05 TR TR2000/02480T patent/TR200002480T2/xx unknown
- 1999-02-05 EP EP04008203A patent/EP1454902A1/de not_active Withdrawn
- 1999-02-05 EP EP99901083A patent/EP1056729B1/de not_active Expired - Lifetime
- 1999-02-05 HU HU0204418A patent/HUP0204418A3/hu not_active Application Discontinuation
- 1999-02-05 CN CN99802628A patent/CN1289326A/zh active Pending
- 1999-02-05 SI SI9930743T patent/SI1056729T1/xx unknown
- 1999-02-22 TW TW088102574A patent/TWI226329B/zh active
- 1999-02-22 GT GT199900022A patent/GT199900022A/es unknown
- 1999-02-23 PE PE1999000156A patent/PE20000334A1/es not_active Application Discontinuation
- 1999-02-24 TN TNTNSN99028A patent/TNSN99028A1/fr unknown
- 1999-02-24 DZ DZ990032A patent/DZ2729A1/xx active
- 1999-02-24 PA PA19998468401A patent/PA8468401A1/es unknown
- 1999-02-25 AR ARP990100791A patent/AR015526A1/es unknown
- 1999-02-25 AP APAP/P/1999/001478A patent/AP9901478A0/en unknown
- 1999-02-26 ZA ZA9901578A patent/ZA991578B/xx unknown
- 1999-03-01 CO CO99012526A patent/CO4980897A1/es unknown
-
2000
- 2000-06-27 IS IS5548A patent/IS5548A/is unknown
- 2000-08-18 OA OA1200000223A patent/OA11450A/en unknown
- 2000-08-22 NO NO20004192A patent/NO20004192L/no not_active Application Discontinuation
- 2000-09-27 BG BG104803A patent/BG104803A/bg unknown
-
2002
- 2002-12-09 US US10/315,369 patent/US6974813B2/en not_active Expired - Fee Related
-
2004
- 2004-08-27 JP JP2004248129A patent/JP2005041879A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE286034T1 (de) | N-((substitutierte fünfgliedrige di- oder triaza- doppeltungesättigter ring)carbonyl)guanidinderivate zur behandlung von ischemie | |
| DE60019556D1 (de) | 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit | |
| DE60019555D1 (de) | 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit | |
| ATE269303T1 (de) | Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen | |
| ATE275145T1 (de) | Chinazolinderivate zur behandlung von tumoren | |
| DE69936890D1 (de) | Vorrichtung zur Behandlung von Ischämie | |
| DE60019158D1 (de) | Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien | |
| ATE417602T1 (de) | Mittel zur behandlung von erkrankungen der speiseröhre | |
| DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
| ATE235481T1 (de) | Substituierte benzopyranderivate zur behandlung von entzündungen | |
| ATE179610T1 (de) | Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten | |
| DE60045386D1 (de) | Gerät zur thermischen behandlung von bandscheiben | |
| DE69821667D1 (de) | Kardioverter zur Behandlung von Vorhofflattern | |
| DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
| ATE295174T1 (de) | Arzneimittel zur behandlung von bluthochdruck | |
| ATE279386T1 (de) | Retinoide zur behandlung von emphysem | |
| DE60031790D1 (de) | Rar-gamma selektive retinoid-agonisten zur behandlung von emphysemen | |
| EP1117431A4 (de) | Behandlung von acidose | |
| DE69807466D1 (de) | Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten | |
| ATE273276T1 (de) | Cyclobutendion-derivate zur behandlung von artherosclerose | |
| ATE253578T1 (de) | Oxazinochinolone zur behandlung von viralen infektionen | |
| DE60021252D1 (de) | Antikonvulsiva zur behandlung von autismus | |
| DE69924379D1 (de) | Verbindungen und zubereitungen zur behandlung der ischämie des gewebes | |
| DE60005685D1 (de) | Oxazinocarbazole zur behandlung von cns-erkrankungen | |
| ATE261965T1 (de) | Bispidin-derivate zur behandlung von herzarrhythmien |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1056729 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |